Mukae et al.

Page 1 of 29

1 Article title:

- 2 A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease
- 3 Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-
- 4 2 Infection: Results of the Phase 2a Part

5

6 Authors:

- 7 Hiroshi Mukae^a, Hiroshi Yotsuyanagi^b, Norio Ohmagari^c, Yohei Doi^{d,e}, Takumi Imamura^f,
- 8 Takuhiro Sonoyama^f, Takahiro Fukuhara^f, Genki Ichihashi^f, Takao Sanaki^g, Keiko Baba^g,
- 9 Yosuke Takeda^f, Yuko Tsuge^f, Takeki Uehara^f*

10

11 Affiliations:

^aDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical

13 Sciences, Nagasaki, Japan

- ^bThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- ¹⁵ ^cDisease Control and Prevention Center, National Center for Global Health and Medicine,
- 16 Tokyo, Japan
- ¹⁷ ^dDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh,
- 18 Pennsylvania, USA
- ¹⁹ ^eDepartments of Microbiology and Infectious Diseases, Fujita Health University School of
- 20 Medicine, Toyoake, Japan
- ^fDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- 22 ^gPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan

23

Mukae et al.

Page 2 of 29

24 ***Corresponding author:**

- 25 Takeki Uehara
- 26 Drug Development and Regulatory Science Division, Shionogi & Co., Ltd.
- 27 Address: 8F, Nissay Yodoyabashi East, 3-3-13 Imabashi, Chuo-ku, Osaka 541-0042, Japan
- 28 Email: <u>takeki.uehara@shionogi.co.jp</u>
- 29 Telephone: +81-6-6209-6907
- 30

Mukae et al.

Page 3 of 29

31 ABSTRACT

32	For the treatment of coronavirus disease 2019 (COVID-19), antiviral agents that can achieve
33	rapid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reduction are warranted.
34	This double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and safety of
35	ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-
36	to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection. Sixty-nine patients enrolled
37	from 56 sites were randomized (1:1:1) to orally receive 5-day ensitrelvir fumaric acid (375 mg
38	on day 1 followed by 125 mg daily or 750 mg on day 1 followed by 250 mg daily) or placebo
39	and followed up until day 28. The primary outcome was change from baseline in SARS-CoV-2
40	viral titer. A total of 16, 14, and 17 patients in the ensiteelvir 125 mg, ensiteelvir 250 mg, and
41	placebo groups, respectively, were included in the intention-to-treat population (mean age: 38.8,
42	40.4, and 38.0 years, respectively). On day 4, the change from baseline in SARS-CoV-2 viral
43	titer ($\log_{10} 50\%$ tissue culture infectious dose/mL) in patients with positive viral titer and viral
44	RNA at baseline was greater with ensiteelvir 125 mg (mean [standard deviation], -2.42 [1.42]; P
45	= 0.0712) and 250 mg (-2.81 [1.21]; $P = 0.0083$) versus placebo (-1.54 [0.74]), and ensitted version of the statement of
46	treatment reduced SARS-CoV-2 RNA by -1.4 to -1.5 log_{10} copies/mL versus placebo. All
47	adverse events were mild to moderate. Ensittelvir treatment demonstrated rapid SARS-CoV-2
48	clearance and was well tolerated in patients with mild-to-moderate COVID-19 or asymptomatic
49	SARS-CoV-2 infection (Japan Registry of Clinical Trials identifier: jRCT2031210350).
50	
51	KEYWORDS: COVID-19, ensitrelvir, Japanese, proof-of-concept study, S-217622, SARS-

52 CoV-2 3C-like protease inhibitor, viral titer

Mukae et al.

Page 4 of 29

53 INTRODUCTION

54	The coronavirus disease 2019 (COVID-19) outbreak, caused by infection with severe acute
55	respiratory syndrome coronavirus 2 (SARS-CoV-2), has quickly spread worldwide and poses a
56	significant public health burden. As of April 11, 2022, nearly 500 million confirmed cases of
57	COVID-19 and more than 6 million deaths associated with COVID-19 have been reported to the
58	World Health Organization (<u>https://covid19.who.int/</u>). Although at least one-third of
59	SARS-CoV-2 infections are asymptomatic (1), the risk of severe COVID-19 is high in
60	approximately one-fifth of infected individuals, particularly in those with underlying health
61	conditions (2). Shedding of infectious SARS-CoV-2 may persist for approximately 10 days in
62	asymptomatic individuals or patients with mild-to-moderate COVID-19 and up to 4 weeks in
63	those with severe disease after symptom onset (3-5). A high viral titer or long persistence of
64	infectious SARS-CoV-2 affects not only the disease severity of infected patients but may also
65	facilitate its spread to their close contacts. Moreover, although vaccination is the cornerstone for
66	controlling COVID-19, it is occasionally associated with post-vaccination breakthrough
67	infections (6). Therefore, from a public health point of view, rapid SARS-CoV-2 reduction in
68	infected patients, in addition to vaccination, is essential for disease control.
69	Several novel treatment options have demonstrated efficacy in reducing the risk of
70	hospitalization, death, or disease progression in patients with COVID-19 at risk of severe
71	disease. These include molnupiravir, a small-molecule ribonucleoside prodrug of
72	N-hydroxycytidine (7); nirmatrelvir, a SARS-CoV-2 3C-like (3CL) protease inhibitor, in
73	combination with ritonavir as a pharmacokinetic booster (8); the SARS-CoV-2 neutralizing
74	monoclonal antibody sotrovimab (9); and the neutralizing antibody cocktail
75	casirivimab/imdevimab (10). In addition, remdesivir has demonstrated efficacy in patients

Mukae et al.

Page 5 of 29

76	hospitalized with COVID-19, with an acceptable safety profile (11). Additional oral antiviral
77	agents that can achieve rapid SARS-CoV-2 reduction as home-based treatment are required for
78	patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection.
79	Ensitrelvir fumaric acid (S-217622; hereafter, ensitrelvir) is a novel oral SARS-CoV-2
80	3CL protease inhibitor that was discovered through joint research by Hokkaido University and
81	Shionogi & Co., Ltd. (12) and is currently developed by Shionogi & Co., Ltd. for the treatment
82	of COVID-19. As the SARS-CoV-2 3CL protease is essential for processing viral complex
83	proteins needed for viral replication (13), its inhibition by ensittelvir is expected to prevent viral
84	replication. Indeed, ensittelvir has shown antiviral efficacy in both in vitro and in vivo animal
85	studies (12, 14). Moreover, its safety, tolerability, and pharmacokinetic profile as single and
86	multiple oral doses have been assessed in a phase 1 study (R. Shimizu, et al., unpublished data).
87	Currently, a multicenter, randomized, double-blind, placebo-controlled, phase 2/3 study is
88	underway to assess the efficacy, safety, and pharmacokinetics of 5-day oral administration of
89	ensitrelvir (Japan Registry of Clinical Trials identifier: jRCT2031210350). Herein, we report the
90	results of the phase 2a part of this phase 2/3 study that assessed the antiviral efficacy and safety
91	of ensitrelvir in patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2
92	infection.

93

94 **RESULTS**

95 **Patient disposition.**

96 This phase 2a part was conducted from September 28, 2021, to January 1, 2022, at 56 sites

97 across Japan (Table S1). Of the 70 patients who provided informed consent and were screened, 1

98 was excluded prior to randomization due to protocol deviation. Among the 69 patients

Mukae et al.

.

Page 6 of 29

99	randomized (ensitelvir 125 mg, 22; ensitelvir 250 mg, 23; and placebo, 24), 1 patient in the
100	ensitrelvir 125 mg group did not receive the study drug and was excluded from the safety
101	analysis set. After receiving the allocated intervention, 3 patients in the placebo group
102	discontinued treatment because of consent withdrawal (2 patients) or disease progression (1
103	patient). None of the female patients discontinued treatment because of pregnancy. Twenty-two
104	patients who tested negative with reverse transcription-polymerase chain reaction (RT-PCR) at
105	baseline (ensitelvir 125 mg, 6; ensitelvir 250 mg, 9; and placebo, 7) were excluded, resulting in
106	47 patients (ensitedvir 125 mg, 16; ensitedvir 250 mg, 14; and placebo, 17) in the intention-to-
107	treat (ITT) population. Following the exclusion of patients without detectable baseline viral titer,
108	43 patients (ensitedvir 125 mg, 15; ensitedvir 250 mg, 14; and placebo, 14) were included in the
109	modified ITT (mITT) population (Fig. 1). All analyses were performed in originally assigned
110	groups.

111 Demographics and clinical characteristics.

112 No notable difference was observed in the baseline demographics and clinical characteristics 113 across treatment groups (Table 1). The mean (standard deviation [SD]) age among the

114 47 patients included in the ITT population was 38.8 (12.5), 40.4 (10.7), and 38.0 (14.2) years in

115 the ensitrelvir 125 mg, ensitrelvir 250 mg, and placebo groups, respectively. None of the enrolled

116 patients were aged > 65 years, and those aged < 20 years were enrolled in the placebo group

117 only. Of the 47 patients, 29 (ensited vir 125 mg, 8 [50.0%]; ensited vir 250 mg, 8 [57.1%]; and

118 placebo, 13 [76.5%]) were men. A majority of the ITT population (40 patients) had mild-to-

119 moderate COVID-19, and 7 (ensitedvir 125 mg, 2 [12.5%]; ensitedvir 250 mg, 2 [14.3%]; and

120 placebo, 3 [17.6%]) were asymptomatic. Among the 47 patients, 42 and 5 were infected with the

121 Delta and Omicron variants, respectively. A majority of the patients in the ITT population had

Mukae et al.

Page 7 of 29

122	been vaccinated (ensitelvir 125 mg, 14 [87.5%]; ensitelvir 250 mg, 12 [85.7%]; and placebo,
123	12 [70.6%]). All vaccinated patients had received 2 doses of mRNA SARS-CoV-2 vaccines,
124	except for 1 patient in the ensitrelvir 125 mg group who received only 1 dose. All patients in the
125	ITT population completed the 5-day treatment, except for 1 patient each in the ensittelvir 125 mg
126	group (did not receive the study drug) and placebo group (discontinued the treatment after day
127	2).
128	SARS-CoV-2 viral titer and viral RNA level.
129	Generally, the SARS-CoV-2 viral titer, measured as log_{10} 50% tissue culture infectious dose
130	$(TCID_{50})/mL$, decreased with time for up to day 4 (3 days after treatment initiation) and
131	remained stable until day 21 in all treatment groups. The SARS-CoV-2 viral titer was
132	significantly lower in the ensitedvir 125 mg (mean [SD], 0.94 [0.29]; $P = 0.0333$) and 250 mg
133	$(0.85 \ [0.19]; P = 0.0059)$ groups versus the placebo group $(1.74 \ [1.17])$ on day 4 (Fig. 2A). The
134	change from baseline in SARS-CoV-2 viral titer on day 4 was greater in the ensitrelvir 125 mg
135	(mean [SD], -2.42 [1.42]; difference from placebo, -0.88; <i>P</i> = 0.0712) and 250 mg (-2.81 [1.21];
136	difference from placebo, -1.27; $P = 0.0083$) groups versus the placebo group (-1.54 [0.74]) (Fig.
137	2B).
138	The SARS-CoV-2 viral RNA level, measured using RT-PCR (log_{10} copies/mL), was
139	significantly lower in the ensitrelvir 250 mg group versus the placebo group on day 4 (mean
140	[SD], 4.005 [0.765] versus 5.067 [1.117]; $P = 0.0084$) (Fig. 2C). The change from baseline in

141 viral RNA level (log₁₀ copies/mL) on day 4 was significantly greater in the ensitedvir 125 mg

142 (mean [SD], -2.677 [1.063]; difference from placebo, -1.408; P = 0.0029) and 250 mg (-2.761

143 [1.291]; difference from placebo, -1.492; P = 0.0039) groups versus the placebo group (-1.269

144 [1.228]). A similar trend of greater change in viral RNA level versus the placebo group was

Mukae et al.

Page 8 of 29

- observed on day 6 in the ensitedvir 125 mg (P = 0.0108) and 250 mg (P = 0.0041) groups and
- 146 day 9 in the ensitedvir 125 mg group (P = 0.0323) (Fig. 2D).
- 147 **Proportion of patients with positive SARS-CoV-2 viral titer.**
- 148 The proportion of patients with positive SARS-CoV-2 viral titer decreased with time from
- 149 baseline to day 21 in all treatment groups. On day 4, the proportion of patients with positive viral
- 150 titer was significantly lower in the ensitedvir 125 mg (26.7%, P = 0.0205) and 250 mg (14.3%, P
- 151 = 0.0033) groups versus the placebo group (71.4%), with a reduction of approximately 60% and
- 152 80%, respectively. Similarly, the proportion of patients with positive viral titer was significantly
- lower in the ensited vir 125 mg group versus the placebo group (0% versus 30.8%, P = 0.0276)
- 154 on day 6 (Fig. S1).

155 **Time to viral clearance.**

- 156 The median time to viral clearance (first negative SARS-CoV-2 viral titer) was significantly
- 157 shorter in the ensited vir 125 mg (61.3 hours; difference from placebo, -49.8 hours; P = 0.0159)
- and 250 mg (62.7 hours; difference from placebo, -48.4 hours; P = 0.0205) groups versus the
- 159 placebo group (111.1 hours). Viral clearance was achieved in all patients in the ensitrelvir 125
- 160 mg and 250 mg groups in less than 120 hours (Fig. 3).

161 COVID-19 symptoms.

162 The mean total score of the predefined 12 symptoms in patients with mild-to-moderate COVID-

- 163 19 showed a decreasing trend with time after treatment initiation in all groups (Fig. 4A).
- 164 Generally, the mean change from baseline in the total score of the 12 COVID-19 symptoms was
- numerically greater in the ensitedvir 125 mg and 250 mg groups versus the placebo group (Fig.
- 166 4B). A decreasing trend from baseline to 120 hours after dose in the 14 COVID-19 symptom
- 167 scores was observed. In particular, the scores for respiratory symptoms (stuffy or runny nose,

Mukae et al.

Page 9 of 29

- sore throat, and cough) and feverish symptoms showed a decreasing trend in patients treated with
- 169 ensitrelvir (Fig. S2).

170 Effects in preventing COVID-19 exacerbations (*post hoc* analysis).

- 171 After treatment initiation, 2 of 14 patients in the placebo group recorded \geq 3 on the 8-point
- 172 ordinal scale of patients' condition (exacerbation), both of whom were unvaccinated. None of the
- 173 patients in the ensitedvir 125 mg (unvaccinated, 2; vaccinated, 11) and 250 mg (unvaccinated, 2;
- 174 vaccinated, 10) groups recorded \geq 3 on the 8-point ordinal scale (Table S2).
- 175 Safety.

176 Treatment-emergent adverse events (TEAEs) were reported in 11 (52.4%), 16 (69.6%), and 9

177 (37.5%) patients in the ensitedvir 125 mg, ensitedvir 250 mg, and placebo groups, respectively,

all of which were mild to moderate in severity. The most common TEAE observed across groups

179 was a decrease in high density lipoprotein (HDL; 3 [14.3%], 12 [52.2%], and 2 [8.3%] patients

180 in the ensitedvir 125 mg, ensitedvir 250 mg, and placebo groups, respectively) (Table 2).

181 Transient decrease and increase in HDL and blood triglyceride levels, respectively, were

182 observed in the ensitedvir groups following treatment initiation but were resolved without

183 additional treatment (Fig. S3). Additionally, an increase in total bilirubin and iron levels was

184 observed in patients receiving ensitrelvir (Fig. S4). Total bilirubin increase observed in 2 patients

185 in the ensitedvir 250 mg group (Table 2) and iron increase observed in 1 patient in the ensitedvir

186 250 mg group were reported as TEAEs. These changes were asymptomatic and transient, and

187 resolved without additional treatment. No obvious changes compared with placebo were

188 observed in haptoglobin, reticulocytes, and low-density lipoprotein in the ensittelvir groups, and

189 no laboratory or clinical signs of hemolysis were observed. No serious TEAEs, deaths, or TEAEs

190 leading to treatment discontinuation were reported (Table 2).

Mukae et al.

Page 10 of 29

191	Treatment-related AEs were reported in 5 (23.8%) and 10 (43.5%) patients in the					
192	ensitrelvir 125 mg and 250 mg groups, respectively. A decrease in HDL and increase in blood					
193	triglycerides were observed to be the most common (≥5% in either group) treatment-related AEs					
194	(Table 2). All treatment-related AEs resolved without sequelae, except for mild					
195	hyperbilirubinemia (total bilirubin level just above the normal range) that lasted until the last					
196	visit (day 28) in 1 patient in the 250 mg group.					
197						
198	DISCUSSION					
199	This is the first clinical study to assess the antiviral efficacy and safety of a novel oral					
200	SARS-CoV-2 3CL protease inhibitor, ensitrelvir, in patients with mild-to-moderate COVID-19					
201	or asymptomatic SARS-CoV-2 infection. This study used infectious viral titer as the primary					
202	endpoint to assess the antiviral efficacy of anti-SARS-CoV-2 agents. A majority of the enrolled					
203	patients had been vaccinated, which reflects the real-world scenario. Our results demonstrated					
204	promising antiviral efficacy of 5-day oral administration of ensitrelvir in rapid viral titer and viral					
205	RNA reduction in this patient population. Patients with mild-to-moderate COVID-19 who were					
206	treated with ensitrelvir showed a trend of symptom relief. Treatment with ensitrelvir was					
207	generally well tolerated.					

As patients with COVID-19 may shed infectious viruses for up to 4 weeks depending on the disease severity (3-5), rapid viral clearance is crucial for disease treatment. In the current phase 2a part, reduction in viral titer and viral RNA was observed after ensitrelvir treatment; this efficacy is comparable with or greater than the findings from clinical trials for other anti-SARS-CoV-2 infection agents (7, 8, 15). Moreover, viral RNA reduction with ensitrelvir was substantial, with a difference from placebo on day 4 reported at -1.4 to -1.5 log₁₀ copies/mL. The

Mukae et al.

Page 11 of 29

214	difference from placebo in viral RNA reduction reported in previous randomized clinical trials
215	on day 5 was -0.547 \log_{10} copies/mL (least-squares mean) for molnupiravir 800 mg (15) and -
216	$0.868 \log_{10}$ copies/mL (adjusted mean) for nirmatrelvir plus ritonavir (8). In addition, previous
217	randomized clinical trials of anti-SARS-CoV-2 agents were conducted in unvaccinated patients
218	(7, 8, 15), whereas most patients in our study had been vaccinated. These results indicate the
219	efficacy of ensitrelvir in the rapid clearance of SARS-CoV-2. From the efficacy of ensitrelvir in
220	rapid viral titer and viral RNA reduction, favorable clinical outcomes, such as earlier symptom
221	relief or prevention of severe COVID-19, are expected.
222	Transient decrease in HDL and increase in triglycerides was observed as TEAEs in the
223	current phase 2a part, which was consistent with the findings derived from the previous phase 1
223 224	current phase 2a part, which was consistent with the findings derived from the previous phase 1 study of ensitrelvir (R. Shimizu, et al., unpublished data). In addition, transient and
223224225	current phase 2a part, which was consistent with the findings derived from the previous phase 1 study of ensitrelvir (R. Shimizu, et al., unpublished data). In addition, transient and asymptomatic increase in total bilirubin and iron levels, which was not associated with signs of
223224225226	current phase 2a part, which was consistent with the findings derived from the previous phase 1 study of ensitrelvir (R. Shimizu, et al., unpublished data). In addition, transient and asymptomatic increase in total bilirubin and iron levels, which was not associated with signs of hepatic or hematologic abnormalities, was observed following ensitrelvir treatment. However,
 223 224 225 226 227 	current phase 2a part, which was consistent with the findings derived from the previous phase 1 study of ensitrelvir (R. Shimizu, et al., unpublished data). In addition, transient and asymptomatic increase in total bilirubin and iron levels, which was not associated with signs of hepatic or hematologic abnormalities, was observed following ensitrelvir treatment. However, the exact mechanism of these laboratory value changes is yet to be elucidated and further
 223 224 225 226 227 228 	current phase 2a part, which was consistent with the findings derived from the previous phase 1 study of ensitrelvir (R. Shimizu, et al., unpublished data). In addition, transient and asymptomatic increase in total bilirubin and iron levels, which was not associated with signs of hepatic or hematologic abnormalities, was observed following ensitrelvir treatment. However, the exact mechanism of these laboratory value changes is yet to be elucidated and further investigation is warranted.

limit concrete conclusions to be drawn from analyses of the clinical outcomes, such as COVID-19 symptoms including respiratory symptoms and disease exacerbation. Second, most of the enrolled patients were infected with the SARS-CoV-2 Delta variant. Our *in vitro* study results suggested that ensitrelvir has antiviral activity against the Omicron variant, which is the most predominant SARS-CoV-2 variant at the time of publication (12). Thus, the clinical efficacy of ensitrelvir against the Omicron variant or future variants of concern needs to be assessed in the subsequent part of this study. In addition, statistical analyses in subgroups, such as minor

Mukae et al.

Page 12 of 29

237	patients and asymptomatic patients, were not feasible owing to the limited number of patients.						
238	Further assessment of the safety and clinical efficacy of ensitrelvir in subsequent clinical studies						
239	is warranted.						
240	In conclusion, treatment with 5-day oral administration of ensitrelvir demonstrated a						
241	rapid clearance of SARS-CoV-2 and was well tolerated in patients with mild-to-moderate						
242	COVID-19 or asymptomatic SARS-CoV-2 infection. The results support further clinical						
243	development of ensitrelvir through large-scale clinical studies for the treatment of mild-to-						
244	moderate COVID-19 or asymptomatic SARS-CoV-2 infection.						
245							
246	MATERIALS AND METHODS						
247	Study design.						
248	Patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection were						
249	randomized (1:1:1) to receive ensitrelvir fumaric acid tablet 125 mg, 250 mg, or matching						
250	placebo. Patients allocated to the ensittelvir groups received a loading dose of ensittelvir on day						
251	1 (375 mg for the 125 mg group and 750 mg for the 250 mg group), followed by the maintenance						
252	dose (125 mg for the 125 mg group and 250 mg for the 250 mg group) on days 2 through 5						
253	without dose modification.						
254	This study was conducted in accordance with the principles of the Declaration of						
255	Helsinki, Good Clinical Practice guidelines, and other applicable laws and regulations. The study						
256	was reviewed and approved by the institutional review boards of all participating institutions						
257	listed in Table S1. All patients or their legally acceptable representatives provided written						
258	informed consent.						

Mukae et al.

Page 13 of 29

259 Patients.

260	Patients (aged 12 to <70 years; body weight ≥40 kg for those aged <20 years to avoid increased							
261	drug exposure) who tested positive for SARS-CoV-2 within 120 hours prior to randomization							
262	were eligible for study enrollment. Results of SARS-CoV-2 antigen tests or nucleic acid							
263	detection testing, including RT-PCR, were used to determine positive SARS-CoV-2 infection.							
264	Patients with mild-to-moderate COVID-19 should have had at least 1 moderate or severe							
265	symptom among the 12 COVID-19 symptoms (stuffy or runny nose, sore throat, shortness of							
266	breath, cough, low energy or tiredness, muscle or body aches, headache, chills or shivering,							
267	feeling hot or feverish, nausea, vomiting, or diarrhea; Table S3), based on the United States Food							
268	and Drug Administration guidance for assessing COVID-19-related symptoms							
269	(https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-							
270	19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs), or							
271	worsening of at least 1 moderate or severe COVID-19 symptom. Patients without the 12							
272	COVID-19 symptoms listed above, anosmia, or dysgeusia within 2 weeks prior to randomization							
273	were classified as those with asymptomatic SARS-CoV-2 infection.							
274	Key exclusion criteria were an awake oxygen saturation of \leq 93% (room air); need for							
275	oxygen administration; worsening of COVID-19 within 48 hours from randomization strongly							
276	suspected by the investigator; suspected active and systemic infections requiring treatment							
277	(except for COVID-19); current or chronic history of moderate or severe liver disease, known							
278	hepatic or biliary abnormalities (except for Gilbert syndrome or asymptomatic gallstones), or							
279	kidney disease; recent blood donation (\geq 400 mL within 12 weeks or \geq 200 mL within 4 weeks							
280	prior to enrollment); use of drugs for COVID-19 within 7 days; and use of strong CYP3A							

Mukae et al.

Page 14 of 29

281	inhibitors	or inducers	or St John'	s wort	products	within	14 days	prior to	o randomization.
							~		

282 Pregnant, possibly pregnant, or breastfeeding women were also excluded.

283 Randomization and blinding.

- 284 Randomization of patients was performed using an interactive response technology system. For
- 285 patients with mild-to-moderate COVID-19, the time from the onset of COVID-19 to
- randomization (<72 hours/≥72 hours) and the presence or absence of COVID-19 vaccination
- 287 were used as stratification factors. For those with asymptomatic SARS-CoV-2 infection, the
- 288 presence or absence of COVID-19 vaccination was used as a stratification factor.
- All patients and study staff were blinded to treatment until the completion of the 28-day
- follow-up period and database lock, except for designated persons at the sponsor and contract
- 291 research organization in charge of statistical analyses. Measurements of SARS-CoV-2 viral titer
- and viral RNA level prior to database lock were allowed in an anonymized manner to avoid
- unexpected unblinding. Emergency unblinding per the investigator's request was allowed only in
- the event of AEs to determine an appropriate therapy for the patient.

295 **Treatment.**

- 296 Patients received allocated study drugs orally (ensitelvir fumaric acid 125 mg, 250 mg, or
- 297 placebo tablets), which were indistinguishable in appearance, labeling, and packaging.
- Use of drugs for the treatment of COVID-19; antiviral, antibacterial, or antifungal drugs (except for external use); antipyretic analgesics other than acetaminophen; antitussives and expectorants; combination cold remedy; and CYP3A substrates was prohibited from study initiation to day 28 or study discontinuation. Strong CYP3A inhibitors or inducers, strong Pglycoprotein or breast cancer resistance protein inhibitors, and other transporter substrates were prohibited from study initiation to 10 days after the last administration of the study drug or study

Mukae et al.

Page 15 of 29

304	discontinuation. Treatment was discontinued in the event of exacerbation of COVID-19, serious
305	or intolerable AEs, pregnancy, or liver function abnormalities.

306 Outcomes and assessments.

307 The primary outcome was a change from baseline (day 1, before drug administration) in SARS-

308 CoV-2 viral titer on days 2, 4, 6, 9, 14, and 21 (or study discontinuation). Secondary outcomes

309 included SARS-CoV-2 viral RNA level, proportion of patients with a positive viral titer, and

- 310 time to viral clearance (first negative SARS-CoV-2 viral titer). SARS-CoV-2 viral titer
- 311 measurement and RT-PCR using nasopharyngeal swabs were performed at Shionogi
- 312 TechnoAdvance Research (Osaka, Japan) and LSI Medience (Tokyo, Japan), respectively.

313 Clinical outcomes included the total score of the 12 COVID-19 symptoms, proportion

314 of patients with anosmia, and those with dysgeusia following treatment in patients with mild-to-

315 moderate COVID-19. Patients assessed their COVID-19 symptoms on a questionnaire (Table

S3) and recorded the scores in a diary twice daily (morning and evening) until day 9 and once

daily (evening) from days 10 to 21. Additionally, disease exacerbations were assessed as a post

318 *hoc* analysis in patients with mild-to-moderate COVID-19. Patients' conditions (exacerbation)

319 were assessed by the investigator using an 8-point ordinal scale (0 = Asymptomatic to 7 = Death,

 ≥ 3 corresponds to hospitalization or worse symptoms; Table S4) on day 1 (before drug

administration) and days 2, 4, 6, 9, 14, 21, and 28 (or study discontinuation).

322 Safety was assessed through TEAEs coded using Medical Dictionary for Regulatory
323 Activities version 24.0. Laboratory tests, vital sign measurements, and electrocardiography were
324 additionally performed. All safety data were evaluated by an independent data and safety
325 monitoring board. Pregnancy tests were performed on day 1 (before drug administration), day
326 28, and at the investigator's discretion for women of childbearing potential.

Mukae et al.

Page 16 of 29

327

328 Statistical analyses.

329	To compare change f	from baseline in SAR	-CoV-2 viral tite	r between each	treatment group and
-----	---------------------	----------------------	-------------------	----------------	---------------------

- the placebo group, 11 patients per group with COVID-19 were required to provide 82.3% power,
- assuming a difference of 2.5 log, a common SD of 2.2 log, and a 2-sided significance level of

332 10%. Based on the phase 2a study of molnupiravir, which reported an infectious SARS-CoV-2

rate of 44% at baseline (15), it was assumed that 50% of patients enrolled in this phase 2a part

334 would have positive RT-PCR results and detectable viral titer at baseline. Thus, the sample size

335 was set to 23 patients per group (69 in total).

All randomized patients who tested positive with RT-PCR at baseline were included in the ITT population. All randomized patients who tested positive with RT-PCR and had detectable SARS-CoV-2 viral titer at baseline were included in the mITT population. All randomized patients who received at least 1 dose of the study drug were included in the safety

340 analysis set.

341 A positive SARS-CoV-2 viral titer was defined as $\geq 0.8 \log_{10} \text{TCID}_{50}/\text{mL}$. SARS-CoV-2 342 viral titer and SARS-CoV-2 viral RNA level were compared between each of the ensitrelyir 343 groups and placebo using the van Elteren test. Median time to viral clearance was compared 344 between each of the ensited virgoups and placebo using a stratified log-rank test. The 345 proportion of patients with positive SARS-CoV-2 viral titer was compared between each of the 346 ensitrelyir groups and placebo using the Mantel-Haenszel test. All statistical tests were 347 performed with stratification by study cohort (mild to moderate or asymptomatic) and at a 2-348 sided significance level of 0.05.

Mukae et al.

Page 17 of 29

349	No prespecified statistical hypothesis was set because this phase 2a part was conducted
350	in an exploratory manner. No imputation was performed for missing data, and multiplicity was
351	not considered. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary,
352	NC, USA).
353	Data availability.
354	Shionogi & Co., Ltd. is committed to disclosing the synopses and results of its clinical trials and
355	sharing clinical trial data with researchers on reasonable request. For further details, please refer
356	to the websites of Shionogi & Co., Ltd.
357	(https://www.shionogi.com/shionogi/global/en/company/policies/shionogi-group-clinical-trial-
358	data-transparency-policy.html) and Vivli (https://vivli.org/).
359	
360	ACKNOWLEDGMENTS
361	The authors and research team thank all patients involved in this study and Masahiro Kinoshita
362	and Satoshi Kojima (Shionogi & Co., Ltd.) for their support for manuscript development.

363 Support for study monitoring and data management was provided by EPS Corporation and

364 funded by Shionogi & Co., Ltd. Medical writing and editorial assistance was provided by Mami

365 Hirano, MS, of Cactus Life Sciences (part of Cactus Communications) and funded by Shionogi

366 & Co., Ltd. All authors retained full ownership of the manuscript content and approved the final

draft for submission.

368	This study was s	ponsored by Shionogi	& Co., Ltd. a	and financially	supported by the
	2		,	2	

- 369 Japan Agency for Medical Research and Development. Employees of Shionogi & Co., Ltd.
- 370 participated in and approved the design and conduct of the study, wrote the protocol, and were

Mukae et al.

Page 18 of 29

371	involved in the collection, management, analysis, and interpretation of data. Institutional authors
372	reviewed and approved the protocol and collected and interpreted the data.
373	H. Mukae has received funding relevant to the submitted work from Shionogi and grants
374	from Taisho Pharma; lecture fees from Pfizer, MSD, Shionogi, and Taisho Pharma; and advisory
375	fees from Pfizer, MSD, and Shionogi outside the submitted work. H. Yotsuyanagi has received
376	consulting fees from Shionogi, lecture fees from Shionogi and ViiV Healthcare, and travel
377	support from Shionogi outside the submitted work. He serves as an advisory board member of
378	Shionogi and President of the Japanese Society of Infectious Diseases. Y. Doi has received
379	grants from Shionogi and Entasis; consulting fees from Shionogi, Meiji Seika Pharma, Gilead
380	Sciences, GSK, MSD, Chugai, and bioMerieux; and lecture fees from MSD, AstraZeneca,
381	Shionogi, and Teijin Healthcare outside the submitted work and serves as an advisory board
382	member of FujiFilm. T. Imamura, T. Sonoyama, T. Fukuhara, G. Ichihashi, T. Sanaki, K. Baba,
383	Y. Takeda, Y. Tsuge, and T. Uehara are full-time employees of Shionogi & Co., Ltd. and may
384	have stocks or stock options. N. Ohmagari declares no conflict of interest.
385	Author contributions: H. Mukae: Conceptualization, Data curation, Supervision, Writing –
386	review & editing. H. Yotsuyanagi: Conceptualization, Data curation, Writing – review & editing.
387	N. Ohmagari: Conceptualization, Data curation, Writing – review & editing. Y. Doi:
388	Conceptualization, Data curation, Writing – review & editing. T. Imamura: Conceptualization,
389	Formal analysis, Supervision, Visualization, Writing – review & editing. T. Sonoyama:
390	Conceptualization, Supervision, Writing – review & editing. T. Fukuhara: Conceptualization,
391	Data curation, Project administration, Writing – review & editing. G. Ichihashi:
392	Conceptualization, Data curation, Project administration, Writing – review & editing. T. Sanaki:
393	Conceptualization, Data curation, Formal analysis, Methodology, Writing – review & editing. K.

Mukae et al.

Page 19 of 29

- 394 Baba: Conceptualization, Data curation, Formal analysis, Methodology, Writing review &
- 395 editing. Y. Takeda: Conceptualization, Data curation, Project administration, Writing review &
- 396 editing. Y. Tsuge: Conceptualization, Project administration, Supervision, Writing review &
- 397 editing. T. Uehara: Conceptualization, Project administration, Supervision, Writing review &
- 398 editing.

399

Mukae et al.

Page 20 of 29

400 **REFERENCES**

- 401 1. Oran DP, Topol EJ. 2021. The proportion of SARS-CoV-2 infections that are
- 402 asymptomatic: a systematic review. Ann Intern Med 174:655–662.
- 403 2. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, Sanderson C,
- 404 McKee M, Troeger C, Ong KL, Checchi F, Perel P, Joseph S, Gibbs HP, Banerjee A,
- 405 Eggo RM. 2020. Global, regional, and national estimates of the population at increased
- 406 risk of severe COVID-19 due to underlying health conditions in 2020: a modelling
- 407 study. Lancet Glob Health 8:e1003–e1017.
- 408 3. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S,
- 409 Zambon M, Gopal R. 2020. Duration of infectiousness and correlation with RT-PCR
- 410 cycle threshold values in cases of COVID-19, England, January to May 2020. Euro
- 411 Surveill 25:2001483.
- Folgueira MD, Luczkowiak J, Lasala F, Pérez-Rivilla A, Delgado R. 2021. Prolonged
 SARS-CoV-2 cell culture replication in respiratory samples from patients with severe
 COVID-19. Clin Microbiol Infect 27:886–891.
- 415 5. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM,
- 416 Okba N, van den Akker JPC, Endeman H, Gommers DAMPJ, Cornelissen JJ, Hoek
- 417 RAS, van der Eerden MM, Hesselink DA, Metselaar HJ, Verbon A, de Steenwinkel
- 418 JEM, Aron GI, van Gorp ECM, van Boheemen S, Voermans JC, Boucher CAB,
- 419 Molenkamp R, Koopmans MPG, Geurtsvankessel C, van der Eijk AA. 2021. Duration
- 420 and key determinants of infectious virus shedding in hospitalized patients with
- 421 coronavirus disease-2019 (COVID-19). Nat Commun 12:267.

Mukae et al.

Page 21 of 29

422	6.	Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, Sabo RT, Hall N,
423		Foreman A, Schubert PL, Gallagher GR, Fink T, Madoff LC, Gabriel SB, MacInnis B,
424		Park DJ, Siddle KJ, Harik V, Arvidson D, Brock-Fisher T, Dunn M, Kearns A, Laney
425		AS. 2021. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine
426		breakthrough infections, associated with large public gatherings - Barnstable County,
427		Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 70:1059–1062.
428	7.	Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos
429		Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A,
430		Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A,
431		Butterton JR, Johnson MG, De Anda C. 2022. Molnupiravir for oral treatment of
432		COVID-19 in nonhospitalized patients. N Engl J Med 386:509-520.
433	8.	Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki
434		M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM. 2022. Oral
435		nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med
436		386:1397–1408.
437	9.	Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E,
438		Solis J, Zheng H, Scott N, Cathcart AL, Hebner CM, Sager J, Mogalian E, Tipple C,
439		Peppercorn A, Alexander E, Pang PS, Free A, Brinson C, Aldinger M, Shapiro AE.
440		2021. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody
441		sotrovimab. N Engl J Med 385:1941–1950.
442	10.	Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper
443		AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C,
444		Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook

Mukae et al.

Page 22 of 29

445		A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos
446		JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L,
447		Braunstein N, Herman G, Yancopoulos GD. 2021. REGEN-COV antibody combination
448		and outcomes in outpatients with COVID-19. N Engl J Med 385:e81.
449	11.	Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E,
450		Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K,
451		Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G,
452		Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G,
453		Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD,
454		Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC. 2020.
455		Remdesivir for the treatment of COVID-19 - Final report. N Engl J Med 383:1813-
456		1826.
457	12.	Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, Maruyama Y,
458		Taoda Y, Kasamatsu K, Suto T, Kouki K, Nakahashi A, Kawashima S, Sanaki T, Toba
459		S, Uemura K, Mizutare T, Ando S, Sasaki M, Orba Y, Sawa H, Sato A, Sato T, Kato T,
460		Tachibana Y. 2022. Discovery of S-217622, a non-covalent oral SARS-CoV-2 3CL
461		protease inhibitor clinical candidate for treating COVID-19. J Med Chem
462		https://doi.org/10.1021/acs.jmedchem.2c00117.
463	13.	He J, Hu L, Huang X, Wang C, Zhang Z, Wang Y, Zhang D, Ye W. 2020. Potential of
464		coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2
465		drugs: insights from structures of protease and inhibitors. Int J Antimicrob Agents
100		56:106055

Mukae et al.

467	14.	McKimm-Breschkin JL, Hay AJ, Cao B, Cox RJ, Dunning J, Moen AC, Olson D,
468		Pizzorno A, Hayden FG. 2022. COVID-19, influenza and RSV: surveillance-informed
469		prevention and treatment - meeting report from an isirv-WHO virtual conference.
470		Antiviral Res 197:105227.
471	15.	Fischer WA, 2nd, Eron JJ, Jr., Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan
472		TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl
473		DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F, Painter WP. 2022. A phase
474		2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-
475		CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med 14:eabl7430.
476		

Mukae et al.

Page 24 of 29

FIGURE LEGENDS

FIG 1 Patient disposition

Patients may be excluded from the analysis populations due to more than one reason.

ITT, intention-to-treat; mITT, modified ITT; RT-PCR, reverse transcription-polymerase chain reaction.

FIG 2 SARS-CoV-2 viral titer as (A) absolute values and (B) change from baseline (mITT population), and SARS-CoV-2 viral RNA level as (C) absolute values and (D) change from baseline (ITT population)

Data are presented as mean \pm SD. **P* < 0.05 versus placebo. The gray, dotted, horizontal

lines in panels (A) and (C) indicate the lower limit of detection of viral titer (0.8 \log_{10}

TCID₅₀/mL) and lower limit of quantification of viral RNA (3.40 \log_{10} copies/mL),

respectively.

ITT, intention-to-treat; mITT, modified ITT; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation; TCID₅₀, 50% tissue culture infectious dose.

FIG 3 Time to viral clearance (first negative SARS-CoV-2 viral titer; mITT population) One patient in the ensitrelvir 250 mg group was excluded from this analysis due to the use of prohibited concomitant drugs on day 1.

CI, confidence interval; mITT, modified intention-to-treat; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

FIG 4 Total score of 12 COVID-19 symptoms in patients with mild-to-moderate COVID-19 as (A) mean absolute value and (B) mean change from baseline (ITT population) COVID-19, coronavirus disease 2019; ITT, intention-to-treat.

Mukae et al.

1 TABLES

2 **TABLE 1** Baseline demographics and clinical characteristics (ITT population)

Variables	Ensitrelvir 125 mg	Ensitrelvir 250 mg	Placebo
	(N=16)	(N=14)	(N=17)
Male sex, n (%)	8 (50.0)	8 (57.1)	13 (76.5)
Age, years, mean (SD)	38.8 (12.5)	40.4 (10.7)	38.0 (14.2)
Patient conditions, $n(\%)^a$			
Hospitalized	6 (37.5)	5 (35.7)	5 (29.4)
Outpatient	1 (6.3)	2 (14.3)	0
Recuperation at hotel	9 (56.3)	7 (50.0)	12 (70.6)
COVID-19 severity, n (%)			
Mild to moderate	14 (87.5)	12 (85.7)	14 (82.4)
Asymptomatic	2 (12.5)	2 (14.3)	3 (17.6)
SARS-CoV-2 variant, n (%)			
Delta	13 (81.3)	13 (92.9)	16 (94.1)
Omicron	3 (18.8)	1 (7.1)	1 (5.9)
Time from onset to randomization, n (%)			

Mukae	et	al.
-------	----	-----

Page 26 of 29

\geq 24 to < 48 hours	1 (6.3)	0	2 (11.8)
\geq 48 to < 72 hours	4 (25.0)	5 (35.7)	3 (17.6)
\geq 72 to < 96 hours	4 (25.0)	4 (28.6)	3 (17.6)
\geq 96 to \leq 120 hours	5 (31.3)	3 (21.4)	6 (35.3)
COVID-19 vaccination history, n (%)	14 (87.5)	12 (85.7)	12 (70.6)
Patients with COVID-19 symptoms, n $(\%)^b$			
Respiratory symptoms			
Stuffy or runny nose	6 (46.2)	4 (33.3)	4 (28.6)
Sore throat	7 (53.8)	2 (16.7)	3 (21.4)
Shortness of breath (difficulty breathing)	1 (7.7)	0	0
Cough	7 (53.8)	7 (58.3)	6 (42.9)
Systemic symptoms			
Low energy or tiredness	6 (46.2)	3 (25.0)	4 (28.6)
Muscle or body aches	2 (15.4)	2 (16.7)	2 (14.3)
Headache	3 (23.1)	2 (16.7)	3 (21.4)
Chills or shivering	4 (30.8)	2 (16.7)	2 (14.3)
Feeling hot or feverish	5 (38.5)	5 (41.7)	3 (21.4)

Mukae e	et al.
---------	--------

Page 27 of 29

Digestive symptoms			
Nausea	0	0	0
Vomiting	0	0	0
Diarrhea	2 (15.4)	1 (8.3)	1 (7.1)
Sensation disturbance			
Anosmia	6 (46.2)	5 (41.7)	7 (50.0)
Dysgeusia	7 (53.8)	3 (25.0)	5 (35.7)
Total score of 12 COVID-19 symptoms, mean $(SD)^b$	10.2 (5.7)	8.8 (4.3)	7.3 (3.6)

3 ^aAt the time of this research, hospitalization was recommended for all patients with COVID-19 in Japan irrespective of disease severity or

4 presence of risk factors. Patients were thus eligible for enrollment in all treatment settings (inpatient, outpatient, recuperation at home, or

⁶ In mild-to-moderate patients in the mITT population (n=13, n=12, and n=14 for the ensited vir 125 mg, ensited vir 250 mg, and placebo groups,

7 respectively).

8 COVID-19, coronavirus disease 2019; ITT, intention-to-treat; mITT, modified ITT; SD, standard deviation.

⁵ recuperation at designated hotels).

Mukae et al.

Page 28 of 29

9 **TABLE 2** Summary of TEAEs (safety analysis set)

Patients with events, n (%)	Ensitrelvir 125 mg	Ensitrelvir 250 mg	Placebo
	(N=21)	(N=23)	(N=24)
Patients with any TEAE	11 (52.4)	16 (69.6)	9 (37.5)
Patients with any serious TEAE or death	0 (0.0)	0 (0.0)	0 (0.0)
Patients with TEAEs leading to treatment discontinuation	0 (0.0)	0 (0.0)	0 (0.0)
TEAEs occurring in \geq 5% of patients in either group			
Nasopharyngitis	2 (9.5)	0 (0.0)	0 (0.0)
Headache	1 (4.8)	3 (13.0)	0 (0.0)
Rhinalgia	2 (9.5)	0 (0.0)	0 (0.0)
High density lipoprotein decreased	3 (14.3)	12 (52.2)	2 (8.3)
Blood triglycerides increased	0 (0.0)	3 (13.0)	0 (0.0)
Aspartate aminotransferase increased	1 (4.8)	1 (4.3)	2 (8.3)
Blood bilirubin increased	0 (0.0)	2 (8.7)	0 (0.0)
Alanine aminotransferase increased	1 (4.8)	0 (0.0)	2 (8.3)
Patients with any treatment-related AE	5 (23.8)	10 (43.5)	0 (0.0)
Treatment-related AEs occurring in \geq 5% of patients in either group			

Mul	cae	et	al.	

Page 29 of 29

High density lipoprotein decreased	3 (14.3)	8 (34.8)	0 (0.0)
Blood triglycerides increased	0 (0.0)	2 (8.7)	0 (0.0)

10 AE, adverse event; TEAE, treatment-emergent AE









Hours

Number of patients

Placebo	14	14	14	11	14	13	13	13	14	11	13	13	12	12	13	11	13	8	9	10	11	10	11	10	9	11	10	9	11	6
Ensitrelvir 125 mg	13	12	12	12	12	12	13	13	12	12	13	12	12	13	12	11	12	2	13	9	13	12	11	11	12	10	11	11	11	4
Ensitrelvir 250 mg	12	12	12	12	12	11	12	12	12	12	12	12	12	12	12	11	11	6	11	11	11	10	11	11	12	10	12	10	9	5

